SanegeneBio licenses RNAi candidate to Genentech for $200M upfrontnews2026-02-02T14:35:38+00:00February 2nd, 2026|Endpoints News|
AstraZeneca pays $1.2B for CSPC’s long-acting obesity drugsnews2026-01-30T10:36:16+00:00January 30th, 2026|Endpoints News|
AstraZeneca makes $15B bet on China to expand manufacturing and R&Dnews2026-01-29T13:39:17+00:00January 29th, 2026|Endpoints News|
Hengrui blazes trail as Chinese drugmakers aspire to go multinationalnews2026-01-28T15:00:06+00:00January 28th, 2026|Endpoints News|
Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharmanews2026-01-27T15:40:01+00:00January 27th, 2026|Endpoints News|
Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcerenews2026-01-27T13:56:41+00:00January 27th, 2026|Endpoints News|
China-founded pharma Corxel raises up to $287M for oral GLP-1news2026-01-22T16:00:43+00:00January 22nd, 2026|Endpoints News|
#JPM26: Hua Medicine plots diabetes drug expansion in China and beyondnews2026-01-22T12:00:28+00:00January 22nd, 2026|Endpoints News|
Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’snews2026-01-21T12:14:26+00:00January 21st, 2026|Endpoints News|
GSK makes $2.2B deal for RAPT and its food allergy candidatenews2026-01-20T10:34:11+00:00January 20th, 2026|Endpoints News|
